tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

AbbVie sees FY24 revenue approximately $55B, consensus $54.6B

Sees FY24: Skyrizi revenue $10.7B; Rinvoq revenue $5.6B; Imbruvica revenue $3.1B; Elahere revenue $450M. Sees FY24 adjusted gross margin 84%. Expects FX to have 0.9% impact on FY sales.

Meet Your ETF AI Analyst

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1